glp-1 sglt2 SGLT-2 Inhibitors and Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease Criteria for recommendation of SGLT2
Description
Because weight loss is not just about pharmacokinetics

Concretely, tobacco smoking, alcohol consumption, unbalanced diet, low fitness, increased BMI as well as unhealthy environmental influences are the key risk factors for the development of T2DM, and this form accounts for 96% of all DM cases [6]

Common Side Effects: Mild nausea (the most common)

GLP-1 therapy belongs to a class of medications called glucagon-like peptide-1 (GLP-1) agonists

Who is the GLP-1 Companion Bundle designed for

Patients can use the NABPs Not Recommended List to determine if their compounding pharmacy is listed
